Luma Vision’s Verafeye platform uses a proprietary catheter sensor in combination with advanced imaging to deliver high-resolution 360-degree images of the beating heart and surrounding anatomy. This gives physicians access to accurate heart data with seamless image integration and an unprecedented field of view. The platform is compatible with other catheters and systems. The German-Irish startup based in Dublin and Munich thus promises treatment with improved success rates and simplified surgical execution.
Fionn Lahart, CEO of Luma Vision, explains:
“Physicians need accurate real-time data directly in the catheterization laboratory to treat their patients. Our goal with Verafeye is to provide the imaging data physicians need to successfully treat as many patients as possible with various cardiac arrhythmias and structural heart disease. We believe that Verafeye can be the foundation of interventional medical imaging for years to come. By developing a technology platform tailored to specific therapies in cardiology, we enable physicians to provide precise treatment for the benefit of patients and the healthcare system.”
Luma Vision developing in Munich
The startup, founded in 2017 by CTO Christoph Hennersperger and CEO Fionn Lahart, has now successfully completed another financing round. Investors provided a total of €20 million ($22 million). The round is led by existing investors EQT Lifesciences, Atlantic Bridge University Fund, and Imec xpand. Atlantic Bridge Growth, Bayern Kapital, and an unnamed international medical technology company also joined the round. The company plans to invest the new capital in further developing the platform with additional clinical applications in cardiology. FDA approval is also in focus.
“We are pleased to work with a company like Luma Vision that is setting new standards in the interventional treatment of widespread heart disease,”
says Monika Steger, managing director of Bayern Kapital. And further:
“Guided from the development office in Munich and from headquarters in Dublin, Luma Vision has the potential to drive global progress in the treatment of heart disease, which comes with an aging society.”
